2012
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. 2012. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs. 21:1247–66. doi:10.1517/13543784.2012.703177.
Concentration of trichloroethylene in breast milk and household water from Nogales, Arizona.
Beamer PI, Luik CE, Abrell L, Campos S, Martinez ME, Sáez AE. 2012. Concentration of trichloroethylene in breast milk and household water from Nogales, Arizona. Environ Sci Technol. 46:9055–61. doi:10.1021/es301380d.
Hospital and medical care days in pancreatic cancer.
Boyd CA, Branch DW, Sheffield KM, Han Y, Kuo Y-F, Goodwin JS, Riall TS. 2012. Hospital and medical care days in pancreatic cancer. Ann Surg Oncol. 19:2435–42. doi:10.1245/s10434-012-2326-2.
The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.
Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA. 2012. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 97:1225–33. doi:10.3324/haematol.2011.048215.
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins.
Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M, Dricot A, Askenazi M, Tavares M, et al. 2012. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 487:491–5. doi:10.1038/nature11288.
Relationship between colorectal cancer screening adherence and knowledge among vulnerable rural residents of Appalachian Kentucky.
Bardach SH, Schoenberg NE, Fleming ST, Hatcher J. 2012. Relationship between colorectal cancer screening adherence and knowledge among vulnerable rural residents of Appalachian Kentucky. Cancer Nurs. 35:288–94. doi:10.1097/NCC.0b013e31822e7859.
A community-based randomized trial of a faith-placed intervention to reduce cervical cancer burden in Appalachia.
Studts CR, Tarasenko YN, Schoenberg NE, Shelton BJ, Hatcher-Keller J, Dignan MB. 2012. A community-based randomized trial of a faith-placed intervention to reduce cervical cancer burden in Appalachia. Prev Med. 54:408–14. doi:10.1016/j.ypmed.2012.03.019.
ACR Appropriateness Criteria® follow-up and retreatment of brain metastases.
Patel SH, Robbins JR, Gore EM, Bradley JD, Gaspar LE, Germano I, Ghafoori P, Henderson MA, Lutz ST, McDermott MW, et al. 2012. ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol. 35:302–6. doi:10.1097/COC.0b013e31824be246.
Melanocortin-3 receptor regulates the normal fasting response.
Renquist BJ, Murphy JG, Larson EA, Olsen D, Klein RF, Ellacott KLJ, Cone RD. 2012. Melanocortin-3 receptor regulates the normal fasting response. Proc Natl Acad Sci U S A. 109:E1489–98. doi:10.1073/pnas.1201994109.
The influence of acute, late-life calorie restriction on whole body energy metabolism in p66Shc(-/-) mice.
Stern JH, Kim K, Ramsey JJ. 2012. The influence of acute, late-life calorie restriction on whole body energy metabolism in p66Shc(-/-) mice. Mech Ageing Dev. 133:414–20. doi:10.1016/j.mad.2012.05.001.
NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling.
Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, Woodford R-MT, Davis BK, Uronis JM, Herfarth HH, et al. 2012. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity. 36:742–54. doi:10.1016/j.immuni.2012.03.012.
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Chambers SK, Chow H-HS, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, et al. 2012. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res. 18:2668–78. doi:10.1158/1078-0432.CCR-12-0261.
A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration.
Bhattacharya MRC, Gerdts J, Naylor SA, Royse EX, Ebstein SY, Sasaki Y, Milbrandt J, DiAntonio A. 2012. A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci. 32:5054–61. doi:10.1523/JNEUROSCI.4951-11.2012.
Investigations of Salmonella enterica serovar newport infections of oysters by using immunohistochemistry and knockout mutagenesis.
Morrison CM, Dial SM, Day WA, Joens LA. 2012. Investigations of Salmonella enterica serovar newport infections of oysters by using immunohistochemistry and knockout mutagenesis. Appl Environ Microbiol. 78:2867–73. doi:10.1128/AEM.07456-11.
Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, Pan Y, Zhao J. 2012. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 426:193–201. doi:10.1016/j.ijpharm.2012.01.020.
Binational arsenic exposure survey: methodology and estimated arsenic intake from drinking water and urinary arsenic concentrations.
Roberge J, O’Rourke MK, Meza-Montenegro MM, Gutiérrez-Millán LE, Burgess JL, Harris RB. 2012. Binational arsenic exposure survey: methodology and estimated arsenic intake from drinking water and urinary arsenic concentrations. Int J Environ Res Public Health. 9:1051–67. doi:10.3390/ijerph9041051.
Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823.
Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823. 2012.
GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.
Rausch MP, Hastings KT. 2012. GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1. J Invest Dermatol. 132:154–62. doi:10.1038/jid.2011.236.
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.
Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Gnerlich J, Darga TE, et al. 2012. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 7:e50141. doi:10.1371/journal.pone.0050141.
2011
Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.
Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C. 2011. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol. 225:479–89. doi:10.1002/path.2971.
End-of-life care in Medicare beneficiaries dying with pancreatic cancer.
Sheffield KM, Boyd CA, Benarroch-Gampel J, Kuo Y-F, Cooksley CD, Riall TS. 2011. End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer. 117:5003–12. doi:10.1002/cncr.26115.
Gle1 is a multifunctional DEAD-box protein regulator that modulates Ded1 in translation initiation.
Bolger TA, Wente SR. 2011. Gle1 is a multifunctional DEAD-box protein regulator that modulates Ded1 in translation initiation. J Biol Chem. 286:39750–9. doi:10.1074/jbc.M111.299321.
Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
Ahluwalia MS, Patel M, Peereboom DM. 2011. Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Rev Anticancer Ther. 11:1739–48. doi:10.1586/era.11.166.
A high-performance microsystem for isolating circulating tumor cells.
Zheng X, Cheung LS-L, Schroeder JA, Jiang L, Zohar Y, . 2011. A high-performance microsystem for isolating circulating tumor cells. Lab Chip. 11:3269–76. doi:10.1039/c1lc20331b.
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Ooi A, Wong J-C, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BWH, Tan M-H, Zhang Z, Yang XJ, et al. 2011. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 20:511–23. doi:10.1016/j.ccr.2011.08.024.